Bristol Myers Squibb CO 8-K filings

Bristol Myers Squibb reported strong second quarter 2026 financial results, driven by its Growth Portfolio, and raised its full-year revenue and EPS guidance.

Bristol-Myers Squibb shareholders re-elected all 11 director nominees and approved executive compensation and the 2026 incentive plan at the annual meeting.

Bristol Myers Squibb announced first quarter 2026 financial results, with total revenues reaching $11.5 billion, a 3% increase year-over-year, driven by strong performance in its Growth Portfolio.

Bristol Myers Squibb announced its Q4 and full-year 2025 financial results, showcasing robust growth in its new product portfolio despite declines in legacy assets, and provided optimistic 2026 guidance.

Bristol-Myers Squibb presented its 'Built for Growth' strategy at the J.P. Morgan Healthcare Conference, highlighting strong 2025 performance and a robust pipeline aimed at sustainable growth into the 2030s.

Bristol Myers Squibb accepted $7.22 billion in principal through amended cash tender offers, set early settlement for November 20, 2025, and expects no further acceptances.

BMS Ireland Capital Funding, a Bristol-Myers Squibb subsidiary, completed a €5 billion public offering of five series of euro-denominated notes with maturities ranging from 2030 to 2055.

Bristol Myers Squibb announced cash tender offers to repurchase up to $7 billion of its outstanding notes, aiming to optimize its debt structure.

Bristol Myers Squibb announced robust third-quarter 2025 financial results, driven by its Growth Portfolio, and raised its full-year revenue guidance.

Bristol Myers Squibb reported a 1% increase in second-quarter revenues to $12.3 billion, driven by strong growth in its Growth Portfolio, while updating its full-year 2025 non-GAAP EPS guidance lower due to a significant acquired IPRD charge.

Bristol Myers Squibb announced the appointment of Dr. Cristian Massacesi as its new Executive Vice President, Chief Medical Officer, and Head of Development, succeeding Dr. Samit Hirawat.

Bristol-Myers Squibb held its annual meeting on May 6, 2025, where shareholders elected directors, approved executive compensation, ratified the appointment of Deloitte & Touche LLP, and voted on shareholder proposals.

Bristol-Myers Squibb announced its Q1 2025 financial results, highlighting growth in its Growth Portfolio and raising its full-year revenue and EPS guidance.

Sandra Leung, Executive Vice President and General Counsel of Bristol-Myers Squibb, has announced her intention to retire in 2025, with a transition period planned until her successor is appointed.

Bristol Myers Squibb's Q4 2024 revenues increased by 8% to $12.3 billion, driven by its Growth Portfolio, while providing 2025 revenue guidance of approximately $45.5 billion.

Bristol-Myers Squibb presented its strategic plan for sustained growth through the end of the decade, emphasizing key marketed products, pipeline advancements, and operational efficiencies.

Bristol Myers Squibb announced an 8% revenue increase in the third quarter of 2024, driven by its growth portfolio, and raised its full-year revenue and earnings per share guidance.

Bristol Myers Squibb announced a 9% increase in second-quarter revenue, driven by its growth portfolio, and raised its full-year non-GAAP earnings guidance.

Bristol Myers Squibb has elected Michael R. McMullen, former CEO of Agilent Technologies, to its Board of Directors, effective July 1, 2024.

Bristol-Myers Squibb shareholders approved an amendment to the company's charter limiting the monetary liability of specified executive officers for breaches of duty of care at the annual meeting on May 7, 2024.

Bristol Myers Squibb's first quarter of 2024 saw revenue growth offset by significant losses due to recent acquisitions, prompting a strategic productivity initiative.

Gerald Storch will not seek re-election to the Bristol-Myers Squibb Board of Directors at the 2024 Annual Meeting, and the board size will be reduced to ten members.

Bristol Myers Squibb has completed its acquisition of Karuna Therapeutics, adding a potential first-in-class schizophrenia treatment to its portfolio.

Bristol-Myers Squibb has successfully priced a $12.5 billion debt offering, including both fixed and floating rate notes, to finance acquisitions and for general corporate needs.

Bristol-Myers Squibb has announced the appointment of Phil Holzer as Senior Vice President and Controller, effective February 15, 2024, replacing Sharon Greenlees who will transition to another role within the company.

Bristol-Myers Squibb advises its shareholders to reject an unsolicited mini-tender offer from Tutanota LLC to purchase up to 500,000 shares at $55 per share.

Bristol Myers Squibb announced its fourth quarter and full-year 2023 financial results, highlighting growth in key products and strategic acquisitions to bolster future growth.